The Comparative Oncology Program of the University of California, Davis Cancer Center focuses on several specific aspects of cancer biology in animals. The first major theme, Tumor Biology, is the study of major Oncogenes, Tumor Suppressor genes. Cancer Stem Cells and Inflammation-Cancer. The second major theme. Genetically Defined Animal Models of Cancer, is the study of tumor development and progression employing transgenic and knockout animal models to elucidate basic mechanisms. The third major theme, Spontaneous Cancers in Large Animals, uses non-rodent animals to study tumor development and invesfigate novel diagnosfics and therapeufics in a preclinical setfing. This program brings a unique combinafion of skills and models to the preclinical setfing. It provides the critical links between bench and bedside. The programmatic goals are: (1) to examine the signaling pathways of oncogenes and tumor suppressor genes and the role of inflammation and cancer stem cells in tumorigenesis using both in vitro systems and genefically defined animal models of cancer in vivo; (2) to characterize genefically induced tumorigenesis in animal models and development of novel animal models and experimental approaches; (3) to characterize spontaneous cancers in large animals and to perform preclinical evaluation of novel diagnostics and therapeutics; and (4) collaboration with other programs to facilitate translational research. The program has 29 members from ten different departments and three schools at UC Davis. It has 17 NClfunded projects for $2.6 million ADC (total peer-reviewed funding, $11.4 million ADC). The group has 524 publications for the last funding period; 21% are inter-programmafic and 10% are intra-programmafic.
This program moves the discovery of new therapies for cancer by taking fundamental cancer discoveries and modeling them in mice. In addifion, the program is unique in having 1300 patients (dogs and cats) that present with cancer to the veterinary school each year. By working together with colleagues treating human pafients, the hope is to bring othenwise not available therapies to our veterinary pafients, while speeding the discovery for new and effective therapies for our human patients.
|Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591|
|Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543|
|Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32|
|Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67|
|York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :|
|Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283|
|(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88|
|Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136|
|Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755|
|Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808|
Showing the most recent 10 out of 733 publications